44. 多発血管炎性肉芽腫症 Wegener granulomatosis Clinical trials / Disease details

臨床試験数 : 92 / 薬物数 : 106 - (DrugBank : 27) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 78

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04316494 (ClinicalTrials.gov)	December 17, 2020	25/2/2020	Hydroxychloroquine in ANCA Vasculitis Evaluation	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial	ANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener Granulomatosis	Drug: Hydroxychloroquine;Drug: Placebo	Guy's and St Thomas' NHS Foundation Trust	Medical Research Council	Recruiting	18 Years	N/A	All	76	Phase 4	United Kingdom
2	EUCTR2018-001268-40-GB (EUCTR)	23/01/2020	13/09/2019	Hydroxychloroquine in ANCA vasculitis	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN	The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tablets	Guy's and St. Thomas' NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	76	Phase 4	United Kingdom